PDCD1 and hepatocellular carcinoma: Immunotherapy is a very promising approach to treat HCC patients, such as PD-1 inhibitors, chimeric antigen receptor T-cell therapy, and adoptive immunotherapy based on NK or γδ T cells, especially for patients who are not candidates for surgery, interventional or patients with recurrence.